Actinium Pharmaceuticals, Inc., a developer of targeted radiotherapies, has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes for Health (NIH), to develop Actimab-A for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies.    Under the agreement, the NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A and Act...